ORIC Pharmaceuticals, Inc. Form 8-K Summary
Filing date: May 6, 2021. This current report discloses a material financing agreement; it does not report quarterly or annual operating results.
Business Context and Reporting Period
ORIC Pharmaceuticals is a Delaware biotechnology company focused on developing oncology programs. The company’s common stock trades on The Nasdaq Global Select Market under the symbol ORIC. The filing relates to an at-the-market equity offering established on May 6, 2021.
Financing and Key Financial Terms
- The company entered into an Open Market Sale Agreement with Jefferies LLC as sales agent.
- ORIC may offer and sell up to $150 million of common stock from time to time.
- The company is not obligated to sell any shares, and the number and timing of sales will be determined by the company, subject to specified parameters.
- Shares may be sold in negotiated transactions or directly on Nasdaq at market prices.
- Jefferies may receive a commission of up to 3.0% of the gross sales price of shares sold.
- The offering is registered under an automatically effective Form S-3 registration statement filed on May 6, 2021.
- The filing does not provide amounts sold, net proceeds received, cash balances, debt, revenue, profit, cash flow, or liquidity metrics as of the filing date.
Use of Proceeds and Material Changes
Net proceeds, if any, together with existing cash, cash equivalents, and short-term investments, are intended to fund development of ORIC-101, ORIC-533, ORIC-944, and ORIC-114; other research and development activities; potential new programs; working capital; and general corporate purposes.
The filing does not identify a prior comparable operating period or report material changes in revenue, profitability, margins, cash flow, debt, or liquidity. No specific acquisition or strategic transaction had been committed to as of the filing date.
Outlook, Risks, and Unusual Items
- Future dilution is possible if the company sells shares under the agreement; the filing does not state the number of shares that could be issued.
- Actual proceeds and dilution will depend on the volume and price of future sales.
- The company may terminate the agreement, and Jefferies may terminate it under specified circumstances, including a material adverse change.
- ORIC agreed to customary representations, warranties, indemnification obligations, and reimbursement of certain expenses.
- The company’s planned use of proceeds depends on continued development of its drug candidates and other research programs, which involve biotechnology development and execution risks.
Investor Verification Items
- Verify whether any shares were sold under the facility and the gross and net proceeds received.
- Review subsequent filings for share issuance, dilution, and remaining capacity under the $150 million program.
- Assess the company’s cash, short-term investments, operating cash burn, and expected funding runway.
- Review clinical and regulatory progress for ORIC-101, ORIC-533, ORIC-944, and ORIC-114.
- Review the complete Sales Agreement and prospectus supplement for detailed termination, indemnification, and offering provisions.